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--I Ef;ect of Time to Thrombolyllc Therapy on infarct 
Size Assessed by Tomographlc Sestemibl 
Perfualon Imaging 
Raymond J. Gibbons, Robin S. Roberts, Timothy R Christian, Salim Yusuf 
for the CORE Investigators. Mayo Clinic, McMaster University; Ham#ton, 
Ontario, CANADA 
Previous attempts to demonstrate an association between infarct size (as 
assessed by left ventdcutsr function) and the duration of chest pain prior to 
initiation of thrombolytic therapy have yielded conflicting results. The CORE 
trial is an international randomized dose-renging trial of peloxamer 198 
which randomized 2,954 patients with acute myocardial infarction (< 12 
hours' duration) between 5/4/94 and 6/25/95. A substudy used tomographic 
sastamibi perfusion imaging to assess infarct size in 1,180 patients. Of these 
patients, 1065 received acute thmmbolytie therapy (efreptokinase or t-PA) 
and had analyzable images. Infarct size as a percent of the left ventricle was 
measured using previously established techniques at a central laboratory. 
The time to thrombelytic therapy was significantly (p = 0.014) associated with 
infarct size: 
"lime to'l~rornpolysis n Infarct Size (% LV) 
< 2 hours 309 19.5 ± 18.8 
2-4 hours 396 22.5 4- 20.0 
4-12 hours 360 23.9 4. 20.5 
After adjustment for infarct location, prior infarct, thrombolytio and dose 
of pofoxamer 188, time remained significant (p = 0.027). However, a 2 hr 
increase in time was associated with an increase in infarct size of only 1.1% 
of the LV, compared to an increase of 8.1% for prior infarction and 16.7°/o for 
anterior infarction. 
Conclusion: "rime to initiation of thrombolytic therapy is a significant de- 
terminant of infarct size as assessed by tomographio sealamibi perfusion 
imaging in the CORE trial. The magnitude of its effect is small compared to 
prior infarction or infarct location. 
"5-'1 The Fate of  Patients With Previous Stroke Given a 
Thrombolysis for  Acute Myocardial  Infarction 
Solomon Behar, David Tarme, Hacoch Hod, Valentina Boyko, 
Shmuel Gottlieb. Neufeld Cardiac, Research Institute, Sheba Medical 
Center, Tel Hashomer, Isra~' 
Patients (pts) with a history of stroke (HS) have a relative centraindication 
for thrombolytic therapy (TT) after acute myocardial infarction (AMI). We 
compared the charectedstica and outcome of lots with HS treated or not 
treated with TT among 2010 unselected lots after AMI, hospitalized in 25 
CCUs in Israel. 
HS and "1"1" HS without'IT p 
(n = 29) (n = 87) Value 
Men (%) 76 72 NS 
Age (mean ± s.d). 72 ± 10 yrs 67 ± 10 yrs 0.01 
Diabetes (%) 24 40 NS 
Hypertension (%) 59 63 NS 
Recurrent MI 34 41 NS 
CHF/P.Edema (%) 21 21 NS 
PAF (%) f0 18 NS 
Cardlogenlc shock (%) 14 7 NS 
Stroke (%) 3 2 NS 
Coronary anglography (%) 14 14 NS 
PTCA/CABG (%) 3 10 NS 
30-day mortality (%) 14 23 NS 
The overall incidence of stroke was similar in both groups. No cases of 
Intracranlal hemorrhage were observed am,~ng pts treated with TT. After 
adjustment for age, CHF, diabetes and PAF, the 30-day mortality odds ratio 
for those treated with TT was 0.63 (90%CI 0.18-2.15). This study suggests 
that selected lOtS with HS may benefit from TT. 
['~"6-3--3-3~ Fibrinolytica vs Primary Angiop lasty  in Acute 
Myocardial  Infarction (FAP): A Randomized Trial in 
a Communi ty  Hospital in Argent ina 
Liliana Gdnfald, Daniel Berrocal, Jorge Balardi, Alejandre Spinetta, Carlos 
Rojas Matas, Pablo Oberti, Heman Doval, Oscar B&zzino, Arturo Cagide. 
Hospital Italiano de Buenos Aires, Argentina 
Percutaneous transluminal coronary angioplasty (PTCA) has became an 
altemaltve to thrombelytios as initial approach in the treatment of acute 
myocardial infarction (AMI). The purpose of this study was to determine if 
primary PTCA: 1) was feasible in our media and 2) could improve the clinical 
and angtographio outcome. Patients (p) within 12 hrs of an AMI, eligible for 
thrombolyals, were included. Exclusion criteria ware cardiagenio shock, and 
LBBB. The end points were: 1) 50% reduction of ST elevation in the EKG at 
120 minutes after randomization and 2) presence of TIMI 3 flow in the infarct 
related artery th the a.-.glogram prior to discharge. A composite of In-hospital 
clinical events (death, extension of MI, development of heart failure, stroke 
and major bleeding) was a secondary end point. From 10/93 to 8/95, 112 
p were randomized to streptokinese (SK) 1.5 K U (58 p) or primary PTCA 
(54 n). Baseline clinical and infarct location characteristics were similarly 
distributed in both groups. The mean age was 66 ± 23 years, with 71% 
male gender. The time from the onset of symptoms to randomization was 
242 4- 138 rain for PTCA and 258 4- 162 for SK (p = NS). The anglngraphio 
success for PTCA was 91%. The interval of time from symptoms onset to 
ST 50% decrease was 325 4- 144 rain for PTCA and 334 ± 151 for SK (p 
= NS). Resolution of ST at 120 mln was 79.6% for PTCA and 50% for SK 
(p = 0,002). In hospital mortality was 9,2°/= for PTCA and 10.3% for SK (p = 
NS). Angfographic follow-up was obtained in 83°/,, of the p in a mean of 8 4- 4 
days. TIMI 3 flow was found in 95% for PTCA and 63.6=/,, for SK (p = 0.001). 
The combined end point of major events was 12.9% for PTCA and 25.8% 
for SK (p = NS). Thus event free survival was 87% and 74% respectively. 
Conclusions: 1) In this study primary PTCA was feasible and as save as SK, 
2) PTCA showed a significantly: a) greater resolution in ST changes and b) 
greater incidence of TIMI 3 flow in the infarct related artery prior to discharge 
than SK. 3) In hospital major events showed a tendency to be reduced with 
PTCA. 
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[ '~'~- '1 Non Q-Wave Infarction Post Myocardial 
Thrombolyais. What Are They Really? (How 
Should They Be Classified?) 
Robert Dupuls, Claude Lauzon, Richard F. Davies, Mado Talajic, Duncan 
J. Stewart, Wayne J. Wamica, Martin Gardner, Bruce Sussex, 
Pierre Savard, Etel Mikes, John Ferguson, Jean L. Rouleau. Thetford 
Mines, Quebec, Canada 
Non Q-wave MI (NQ) differ from Q-wave MI (Q) for their natural evolution, 
Thrombolyals (TL) has increased the number of NQ resulting from aborted 
transmural MI. How do they evolve and how should they be classified remains 
unclear. CAMI is a Canadian multicenter study where 4133 consecutive MI 
were prospectively recruited between 1990 and 1992. Transferred patients 
(1007) were excluded and 2368 accepted a complete follow-up. We com- 
pared Q and NQ with or without TL. 
~ariables Q post Q No NQ post NQ No 
TL(1) TL(2) TL(3) 1"1 ~4) 
N (%) 1003 (32) 760 (24) 339 (11) 1024 (33) 
1vs3 3v04 
21 daysdeath* 69(6.9) 115 (15) 24(7.1) 98 (9.6) NS NS 
1 y. death* 105 (11) 162 (21) 38 (11) 182 (18) NS & 
1 y. rec Ml** 60 (7,6) 52 (9.3) 26 (9.6) 67 (9.0) NS NS 
1 y. rec Ang °° 375 (47) 269 (48) 150 (55) 384 (52) # NS 
PTCA (1 y,)** 227 (29) 104 (19) 90 (33) 188 (21) NS & 
CABG (1 y.)** 87 (11) 74 (13) 36 (13) 131 (18) NS NS 
• On total cohort (3126), °, with complete follow-up, #p < 0.05, Sp < 0.01 
All groups showed significant baseline characteristic differences, Previous 
MI, PTCA and CABG conferred a much higher risk to develop a NQ either 
with or without TL TL was the most important prognostic factor and both 
groups post TL (Q or NQ) showed identical outcome (cf Table). 
We conclude that NQ post TL behave like Q pest TL and has a much better 
prognosis than NQ without TL Therefore they should be considered either 
as a special category of MI or together with Q for future studies. 
~ Nonfatal Reinfarction as an Independent 
Riskfactor for Subsequent Mortality in 
Post-Myocardial Infarction Patients 
Ran I". van Domburg, Jaap W. Deckers, Afda J. Azar, Paul RM.M. van 
Bergen, Jan J.C. Janker. University Hospital Dijkzigt and Erasmus 
University Rotterdam, The Netherlands 
The independent risk carded by nonfatal rsinfarction for subsequent death 
has seldom been quantified. The p:'ognostic significance of nonfatal re- 
infarction was determined from the ASPECT trial database. From 1986 
till 1992 3404 pest-myocardial infarction patients were assigned to long- 
